| GHS 分類 | WarningH315 (98.9%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 174 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|
| その他の安全情報 | IMAP assessments - L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-: Environment tier I assessment |
|---|
| FDA 要件 | Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392). |
|---|
| Special Reports | Hays MTJ Clin Endocrinol 63: 527 (1970). Absorption of triiodothyronine in man.Surks MI, et alJ Clin Invest 52: 805 (1973). Determination of iodothyronine absorption and conversion to L-thyroxine (T4) to L-triiodothyronine (T3) using a rate turnover technique. |
|---|
| Hazard Classes and Categories | Skin Irrit. 2 (98.9%) |
|---|
| 保管条件 | Commercially available liothyronine sodium tablets should be stored in tight containers at a temperature less than 40 °C, preferably between 15-30 °C. Commercially available liothyronine sodium injection should be stored at 2-8 °C. /Liothyronine sodium/ |
|---|
| 処分方法 | SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices. |
|---|
| 相互作用 | USE OF PROPRANOLOL IN CONJUNCTION WITH REPLACEMENT THERAPY HAS BEEN REPORTED TO DECR RISK OF ARRHYTHMIA & ANGINA...THYROID COMPOUNDS THAT PRODUCE HYPERMETABOLIC STATE (LIOTHYRONINE...) INCR RATE OF DECAY OF VITAMIN K-DEPENDENT CLOTTING FACTORS, & IN PRESENCE OF ORAL ANTICOAGULANTS /EG, WARFARIN/, NORMAL COMPENSATION BY INCR SYNTHESIS IS PREVENTED.THERE IS CONSIDERABLE CLINICAL EVIDENCE THAT A PATIENT'S THYROID STATE AFFECTS RESPONSE TO TRICYCLIC ANTIDEPRESSANT DRUGS. ADDITION OF LIOTHYRONINE (25 UG/DAY) MAY PREVENT RELATIVELY LONG LAG TIME THAT OCCURS BEFORE CLINICAL EFFECTIVENESS OF TRICYCLIC ANTIDEPRESSANTS IS OBSERVED.CHOLESTYRAMINE MAY CAUSE CLINICALLY SIGNIFICANT DECR IN ABSORPTION OF THYROID HORMONE WHEN THESE DRUGS ARE GIVEN SIMULTANEOUSLY. /THYROID HORMONE/For more Interactions (Complete) data for LIOTHYRONINE (16 total), please visit the HSDB record page. |
|---|
| 暴露経路 | 95% in 4 hours |
|---|
| Milk Concentrations | Although only minimal amounts of thyroid hormones are distributed into milk. ... /Thyroid agents/ |
|---|
| 毒性の概要 | The hormones, T<sub>4</sub> and T<sub>3</sub>, are tyrosine-based hormones produced by the thyroid gland. Iodine is an important component in their synthesis. The major form of thyroid hormone in the blood is thyroxine (T<sub>4</sub>). This is converted to the more active liothyronine form by deiodinases in peripheral tissues. Liothyronine acts on the body to increase the basal metabolic rate, affect protein synthesis and increase the body's sensitivity to catecholamines (such as adrenaline). The thyroid hormones are essential to proper development and differentiation of all cells of the human body. To various extents T<sub>4</sub> and T<sub>3</sub> regulate protein, fat and carbohydrate metabolism. Their most pronounced effect is on how human cells use energetic compounds. The thyroid hormone derivatives bind to the thyroid hormone receptors initially to initiate their downstream effects. |
|---|
| Human Toxicity Excerpts | UNTOWARD EFFECTS OF OVERDOSES OF THYROID HORMONES INCL TACHYCARDIA...ANGINA PECTORIS, HYPERTENSION...HYPERKINESIS...GI DISTURBANCES, & HYPOADRENOCORTICISM. ...MAY CAUSE ALLERGIC REACTIONS. /THYROID HORMONES/FRANKLY TOXIC DOSES INDUCE UNPLEASANT BUT TRANSIENT SYMPTOMS THAT RESEMBLE THYROTOXICOSIS (THYROID STORM). SIGNS & SYMPTOMS INCL PALPITATIONS, RAPID & IRREGULAR PULSE, HEADACHE, TREMORS, NERVOUSNESS, INSOMNIA, DELIRIUM, DIAPHORESIS, HYPERPYREXIA, VOMITING (SOMETIMES UNCONTROLLABLE), COLLAPSE & COMA. /THYROID/LOW TOXICITY @ NORMAL DOSAGE. |
|---|
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
|---|
| Drug Induced Liver Injury | Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)liothyronineTriostat®Thyroid agentsNot Applicableno-DILI-concern |
|---|
| Non-Human Toxicity Excerpts | IN RATS EXOPHTHALMOS HAS BEEN PRODUCED /BY USE OF LIOTHYRONINE/. IN RABBITS INTRAOCULAR PRESSURE HAS BEEN REDUCED 4 MM HG BY SUBCONJUNCTIVAL INJECTION OF TRIIODOTHYRONINE...Four pregnant New Zealand white rabbits received intramuscular triiodothyronine (LiothyronineT3) at 125 ug/kg on days 25 and 26 of gestation. Another group of 6 rabbits served as controls. Maternal and fetal plasma-free T3, thyroxine (T4), and glucose concentration, as well as fetal liver glycogen content, were evaluated on day 27 of gestation. In T3-treated rabbits, maternal and fetal plasma-free T3 concentration was higher than in controls. T3 treatment resulted in fetal hyperglycemia and depletion of fetal liver glycogen content. |
|---|
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
|---|
